Last verified: April 22, 2026 · 8 Kaiser formularies audited · FDA, Lilly, CMS, and DMHC sources confirmed
Insurance Coverage Guide · April 22, 2026
Does Kaiser Cover Foundayo? What We Actually Verified in 2026
Last reviewed:
Last verified: April 22, 2026 · By The RX Index Editorial Team
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
Short answer: does Kaiser cover Foundayo?
For most Kaiser members right now, the honest answer is no — and we can show you the receipts. As of April 22, 2026, we searched eight of Kaiser Permanente’s current public 2026 formulary documents for “Foundayo” and “orforglipron” and found zero matches [¹]. Foundayo was only FDA-approved on April 1, 2026 [²], and Kaiser’s California plan documents already exclude drugs “prescribed solely for weight loss” unless medically necessary for morbid obesity with program participation [³].
But “Kaiser never covers it” would be dishonest. Two lanes still matter: federal and postal employees on Kaiser FEHB or PSHB plans have published access to GLP-1s and oral anti-obesity medications at 50% coinsurance with prior authorization [&sup4;], and Kaiser Northwest has a published Wegovy coverage criteria document that proves Kaiser can build a weight-loss GLP-1 pathway when it chooses to [&sup5;].
| Your situation | Answer based on what we verified | Best next step |
|---|---|---|
| Standard Kaiser commercial / marketplace | No public Foundayo listing found in any 2026 formulary audited | Verify your plan, weigh the exception path, or go cash-pay |
| Kaiser FEHB / PSHB (federal/postal) | Real published access lane at 50% coinsurance with PA [&sup4;] | Verify Foundayo specifically + PA criteria + program |
| Kaiser Medicare Advantage / Part D | Not in formularies; Medicare GLP-1 Bridge covers Foundayo at $50/month starting July 1, 2026 [&sup7;] | Meet CMS eligibility; provider submits PA to CMS central processor |
| Kaiser Northwest | Published Northwest criteria for Wegovy exist [&sup5;]; Foundayo specific not yet published | Ask whether Foundayo criteria are published; file exception if not |
| Kaiser via Medi-Cal | No — Medi-Cal Rx excluded GLP-1s for weight loss effective January 1, 2026 [&sup8;] | Cash-pay is effectively the only weight-loss pathway |
| Already denied | The denial is not the end of the road | File exception → grievance → IMR (California) or IRO (Washington) |
Last verified April 22, 2026. Kaiser formularies update monthly.
Want Ro to pull your Kaiser coverage details before you commit to anything?
Ro contacts your insurer, reports back whether prior authorization is required, and tells you what you’d actually pay. No Ro membership required to run the check.
Use Ro’s free GLP-1 Insurance Coverage Checker →Before you spend 10 minutes on the phone: use the Kaiser call script
The single most useful thing you can do before calling Member Services is to have the right questions ready. We’ve embedded the complete Kaiser Foundayo call script in the How to verify your plan section below. It asks every question that determines your real Foundayo path. One page. Seven questions. The answers tell you which path actually applies.
The RX Index Kaiser–Foundayo Public Coverage Audit (April 2026)
Most articles answering “does Kaiser cover Foundayo” just say coverage varies, check your plan. That’s not an answer. It’s a shrug. We opened the PDFs.
On April 22, 2026, we opened eight current Kaiser Permanente 2026 formulary documents and searched each one for the drug names “Foundayo” and “orforglipron.” Zero public matches were found.
| Kaiser document checked (2026) | Foundayo / orforglipron found? | What the document says about non-listed drugs |
|---|---|---|
| Kaiser 2026 CA Commercial Marketplace Formulary (eff. 04/07/2026) | Not found [&sup9;] | Coverage details in EOC; monthly formulary updates; exception process available |
| Kaiser 2026 CA Commercial HMO (Southern CA, upd. 03/01/2026) | Not found [¹°] | EOC governs; monthly changes; exception process available |
| Kaiser 2026 Northwest Commercial Formulary (upd. 03/19/2026) | Not found [¹¹] | Non-formulary exception through Formulary & Therapeutics Committee |
| Kaiser 2026 Washington Marketplace Formulary | Not found [¹²] | Exception process with IRO external review rights |
| Kaiser 2026 Medicare Comprehensive Formulary (eff. 04/01/2026) | Not found [¹³] | Exception pathway for non-formulary Part D drugs |
| Kaiser 2026 Medicare PDP Comprehensive Formulary (WA) | Not found [¹&sup4;] | Exception process applies |
| Kaiser Permanente Insurance Company (KPIC) POS Formulary | Not found [¹&sup5;] | Routed through MedImpact |
| Kaiser “Your weight loss medication coverage” member bulletin | GLP-1s not covered for weight-loss purpose [¹&sup6;] | Internal weight-management program remains part of base coverage |
Two things are true at once. First, no standard Kaiser commercial or Medicare member should walk in expecting Foundayo at a normal copay right now. Second, “not on the formulary” doesn’t mean “permanently blocked.” Kaiser’s own documents describe a formulary exception process, and in several regions, an external review pathway if the exception is denied.
Why Kaiser generally restricts GLP-1 weight-loss coverage
Kaiser Permanente is different from most insurers because Kaiser is the insurer and the medical group. Kaiser’s Pharmacy and Therapeutics Committees decide what’s on each regional formulary, and Kaiser’s own 2025 California EOC documents explicitly exclude drugs “prescribed solely for weight loss” except when medically necessary for morbid obesity and when enrolled in a covered comprehensive weight-loss program [³]. Three specific primary-source facts tell the story:
- 1. Kaiser 2025 California individual and family plan language: “Drugs prescribed solely for weight loss or for cosmetic purposes” are excluded from the Outpatient Prescription Drug benefit, except when medically necessary for morbid obesity and when enrolled in a covered comprehensive weight-loss program [³]. Foundayo walks into this same exclusion framework unless you qualify under the morbid-obesity exception with program participation.
- 2. Medi-Cal Rx, effective January 1, 2026: California’s Medicaid drug program removed GLP-1 weight-loss drugs from the Contract Drugs List. Existing prior authorizations for weight loss ended December 31, 2025 [&sup8;]. This affects Kaiser Medi-Cal members, not Kaiser commercial or employer-sponsored members.
- 3. Kaiser Northwest semaglutide (Wegovy) criteria: Where Kaiser does cover a weight-loss GLP-1, the rules are tight. For Wegovy, Kaiser Northwest’s published criteria include BMI thresholds, weight-management program requirements, liver-enzyme and alcohol-consumption exclusions, and step therapy including an adequate trial of semaglutide (Ozempic) [&sup5;].
Kaiser lanes that still have a real path
Kaiser Foundayo access is unequal by plan lane. Here’s how the lanes stack up, with the source-of-truth for each claim.
Foundayo at a glance: FDA-approved brand-name medication · Oral GLP-1 tablet · Once daily · No food or water restrictions
| Kaiser lane | What’s publicly stated | What we verified | External review / appeal |
|---|---|---|---|
| Standard commercial / marketplace | GLP-1 weight-loss access restricted; morbid-obesity exception with program [³] | No Foundayo listing in 8 formularies audited | Internal exception; external review varies by state |
| FEHB / PSHB (federal/postal) | GLP-1 and oral anti-obesity at 50% coinsurance with PA and program [&sup4;] | Foundayo not specifically named; framework applies to drug class | Federal appeal rights; OPM oversight |
| Medicare Part D (standard) | Exception process for non-formulary drugs [¹³] | No Foundayo listing in 2026 Medicare formularies | Part D appeal process |
| Medicare GLP-1 Bridge (separate from Part D) | $50/month copay; starts July 1, 2026; Bridge extends through Dec 31, 2027 [&sup7;] | CMS explicitly includes Foundayo (added April 6, 2026) | Provider submits PA to CMS central processor (Humana) |
| Medi-Cal (California) | GLP-1s excluded for weight loss eff. Jan 1, 2026 [&sup8;] | Adults have no weight-loss coverage path | Medi-Cal fair hearing; EPSDT for under-21 |
Kaiser FEHB / PSHB — the strongest lane
Kaiser’s public materials for FEHB and PSHB programs describe access to GLP-1s and oral anti-obesity medications, typically at 50% coinsurance, with prior authorization and weight-management program participation required [&sup4;]. This is not a Foundayo-specific guarantee — no public Kaiser document we checked has Foundayo on it yet — but it is a real, published access framework that most commercial Kaiser plans don’t offer.
Practical read: if you’re on Kaiser FEHB or PSHB, verify Foundayo status directly with Member Services before assuming exclusion. The fact that your plan already funds oral anti-obesity drugs under defined criteria is the most favorable possible starting point.
Kaiser Northwest — the weight-loss GLP-1 precedent
Kaiser Northwest has a published Clinical Oversight Review Board criteria document for semaglutide (Wegovy) [&sup5;]. That document establishes that Kaiser Northwest already has the administrative infrastructure to evaluate, gate, and cover a weight-loss GLP-1. Published criteria include coverage only when the member’s benefit includes weight-loss medications, BMI thresholds, adequate trial of semaglutide (Ozempic), and specific liver-enzyme and alcohol-consumption exclusions.
What this means for Foundayo: when Kaiser Northwest’s Formulary & Therapeutics Committee evaluates Foundayo, the framework is already built. If you’re a Kaiser Northwest member, ask your provider whether Foundayo-specific criteria have been published yet, and if not, reference the existing Northwest weight-loss GLP-1 framework when requesting an exception.
Kaiser standard commercial / marketplace — the hardest lane
This is where most Kaiser members sit, and it’s the hardest of the active paths. Your options in order of realism: (1) formulary exception with strong medical-necessity documentation, (2) external review if you have that right under your plan and state, (3) cash-pay through LillyDirect or Ro while Kaiser’s position evolves.
Kaiser Medi-Cal — the closed door
Medi-Cal Rx excluded GLP-1 medications for weight loss indication effective January 1, 2026 [&sup8;]. There is no Kaiser-level override for Medi-Cal members. Cash-pay is effectively the only path, and for most Medi-Cal households that’s not a realistic answer.
How to verify your exact Kaiser plan in under 15 minutes
The fastest reliable verification is a 10-minute phone call using the exact question script below, which covers everything that determines your real Foundayo path.
Step 1: Identify your Kaiser region and plan type
Your region is printed on your Kaiser ID card. Your plan type (HMO, Medicare Advantage, FEHB, PSHB, KPIC POS) determines which formulary applies to you.
Step 2: Open the 2026 formulary for your plan
Go to kp.org/formulary, select your region, open the formulary PDF that matches your plan, and use Ctrl+F (or Command+F) to search “orforglipron” and “Foundayo.” As of April 22, 2026, you should expect to find neither — but this is how you verify for the day you’re reading.
Step 3: Sign into kp.org and check your benefits
Your signed-in benefits page tells you whether your plan includes a weight-loss medication benefit at all. This single fact often decides the entire conversation. If your plan does not include weight-loss medication coverage as a benefit category, no prior authorization or formulary exception will save you — the coverage isn’t in your contract.
Step 4: Call Kaiser Member Services with this exact script
Use the phone number on the back of your ID card. Ask every one of these questions. Write down the answers and the rep’s name.
“Hi, I’d like to check coverage for a specific drug.
- 1. Is Foundayo — F-O-U-N-D-A-Y-O, generic name orforglipron — on my plan’s formulary today?
- 2. If it’s not on formulary, is there a formulary exception process I can request? What does my provider need to submit?
- 3. Is prior authorization required if the drug is covered? What are the PA criteria?
- 4. Is my plan’s weight-loss medication benefit active, or is weight-loss drug coverage excluded from my plan entirely?
- 5. Would this be processed under my pharmacy benefit or my medical benefit?
- 6. What is your name and a reference number for this call?”
If Kaiser says no, ask: “Is this a non-formulary issue, a PA denial, or a benefit exclusion?” The kind of no determines your entire next step.
If you prefer to hand the verification work to someone else entirely, Ro’s free insurance checker contacts your plan and reports back on coverage, prior authorization, and your likely cost.
Start Ro’s free Foundayo coverage check →If Kaiser says no — your three real paths forward
A Kaiser Foundayo denial has three escalating responses: (1) a formulary exception, (2) a grievance if the exception is denied, and (3) for California members, an Independent Medical Review through the DMHC. If those fail or take too long, cash-pay via LillyDirect or Ro gets you on medication within about a week.
Foundayo is a brand-name FDA-approved oral GLP-1.
Path 1: Formulary exception
Your Kaiser provider files the exception with medical-necessity documentation. Kaiser is required to issue a standard coverage decision within 72 hours of receiving your prescriber’s supporting statement, or within 24 hours for expedited requests when your health could be harmed by waiting.
What strengthens the exception:
- Documented BMI and at least one serious weight-related comorbidity (hypertension, dyslipidemia, Type 2 diabetes, sleep apnea, cardiovascular disease)
- Documented failure or intolerance of prior weight-loss interventions
- A specific medical reason you need the oral format (e.g., documented needle-related anxiety or injection-site issues)
- Reference to existing Kaiser weight-loss GLP-1 coverage frameworks in your region where applicable
What kills the exception:
- No weight-loss-medication benefit in the plan at all — this is a plan-design issue, not a documentation issue
- Documentation that doesn’t meet your plan’s published criteria
Path 2: Grievance
If the exception is denied, file a grievance with Kaiser Member Services. Kaiser is required to acknowledge and decide within timeframes defined by your plan type and state. Grievances sometimes overturn denials where the initial reviewer missed clinical documentation. Internal grievance is usually not the winning step — external review is.
Path 3 (California): DMHC Independent Medical Review
California members have an external-review right that members in other states don’t. The Department of Managed Health Care assigns your case to an independent physician who is not a Kaiser employee. Kaiser is bound by the IMR decision.
| DMHC IMR verified stat | Verified figure |
|---|---|
| IMR requests resulting in service being provided | ~73% [²¹] |
| Urgent IMR decision timeline | 7 days [²²] |
| Non-urgent IMR decision timeline | 45 days after documentation [²²] |
| Cost to file | Free |
Important scope limitation: if Kaiser’s denial is that Foundayo is not a covered benefit under your plan (not a medical-necessity dispute), DMHC may route your case as a consumer complaint rather than an IMR. Know which kind of denial you have before you file [²²].
File at healthhelp.ca.gov or call the DMHC Help Center at 1-888-466-2219. Washington members have parallel external review through an IRO as explained in your Kaiser Washington EOC.
Path 4 (the one most Kaiser members actually take): cash-pay
Kaiser exceptions and external reviews take weeks. For many members, the realistic route to a first dose — and the long-term plan if Kaiser won’t add Foundayo to standard coverage — is to pay cash. The next section shows exactly what that looks like.
See Foundayo availability and cash pricing on Ro →What Foundayo actually costs — five paths compared
Short answer: Foundayo’s official Lilly cash price starts at $149/month for the 0.8 mg starter dose [&sup6;], rises to $199/month at 2.5 mg, and settles at $299/month for 5.5–17.2 mg doses when refilled within 45 days ($349/month for the top two doses without timely refills). With commercial insurance coverage + Foundayo Savings Card: as low as $25/month.
Provider-stated vs. verified pricing (verified April 22, 2026)
| Price point | Lilly (manufacturer) | Ro (telehealth) | Sesame Care |
|---|---|---|---|
| 0.8 mg starter | $149/mo [&sup6;] | $149 first month [¹⁹] | Follows Lilly ladder |
| 2.5 mg | $199/mo [&sup6;] | $199/mo [¹⁹] | Follows Lilly ladder |
| 5.5–17.2 mg | $299/mo (45-day refill); $349 top 2 doses without [&sup6;] | $199–$299/mo [¹⁹] | Follows Lilly ladder |
| With commercial coverage + Savings Card | As low as $25/mo; $100 max monthly savings [&sup6;] | Same savings card applies | Same savings card applies |
| Medicare/Medicaid/TRICARE/VA (Savings Card) | Excluded by federal law [&sup6;] | Excluded | Excluded |
| Monthly membership (not medication) | None — pharmacy only | Ro Body: $39 first month; as low as $74/mo annual prepay [¹⁹] | Separate subscription fee |
Full Kaiser-member access paths
| Access path | Medication cost | Membership / program | Time to first dose | Best for |
|---|---|---|---|---|
| Approved Kaiser formulary exception | Standard plan copay | N/A (Kaiser is your PCP) | 72 hrs – 6 weeks | Members meeting strict medical-necessity criteria with weight-loss-medication benefit |
| DMHC IMR (CA) after medical-necessity denial | Plan copay if overturned | Free to file [²²] | 7 days urgent / 45 days non-urgent | California members denied on medical-necessity grounds |
| LillyDirect self-pay | $149 / $199 / $299 / $349 by dose [&sup6;] | No membership | 5–10 days | Lowest all-in cost; no telehealth support |
| Ro cash-pay + Ro Body | $149 mo 1; $199–$299 after [¹⁹] | $39 first month; as low as $74/mo annual prepay [¹⁹] | ~7 days | Clinical support + insurance concierge |
| Medicare GLP-1 Bridge (eligible) | $50/month [&sup7;] | N/A | Starts July 1, 2026 | Medicare members who meet CMS eligibility |
Ro vs. LillyDirect vs. Sesame after a Kaiser no
Ro — best for Kaiser denial scenario
- Free insurance checker runs before you commit
- Care team + titration guidance + 24/7 access
- Insurance concierge keeps checking if Kaiser changes
- Medication: $149 mo 1 + Ro Body membership fee
LillyDirect — lowest all-in cost
- Direct brand-name cash-pay; no membership fee
- Ships from Amazon Pharmacy, Walmart, Prescryptive
- Need a prescription from any licensed U.S. provider
- Your Kaiser doctor can write it at clinical discretion
Sesame Care — valid alternative
- Telehealth with its own subscription fee
- Medication pricing follows the Lilly ladder
- Good alternative if Ro isn’t your fit
Note on Ro + Kaiser HMO: Ro cannot function as a Kaiser in-network prescriber. Kaiser is a closed HMO — Kaiser benefits apply only when a Kaiser-affiliated provider writes the prescription. But because Kaiser isn’t covering Foundayo for most members anyway, the Kaiser-internal path isn’t winning most people anything. Ro serves Kaiser members who’ve accepted they’ll be paying cash.
Ro’s free GLP-1 Insurance Coverage Checker will tell you where Kaiser stands before you commit. If Kaiser won’t cover it and you decide to move forward, you can start Foundayo cash-pay at $149/month + Ro Body membership.
Start Ro’s free Foundayo coverage check →Disclosure: The RX Index may earn a commission when readers sign up via affiliate links. Commissions never influence clinical guidance.
Kaiser Medicare Advantage members: the Medicare GLP-1 Bridge changes the math
Starting July 1, 2026 and running through December 31, 2027, the CMS Medicare GLP-1 Bridge will provide Foundayo, all Wegovy formulations, and the Zepbound KwikPen at a $50/month copayment for eligible Medicare Part D beneficiaries [&sup7;]. Part D sponsors do not have to opt in — the Bridge operates outside standard Part D through a central CMS processor (Humana). Foundayo was explicitly added to the Bridge on April 6, 2026 [&sup7;].
Who’s eligible: verified CMS criteria (three lanes)
| Lane | Eligibility criteria (at initiation) [&sup7;] |
|---|---|
| Lane 1 | BMI ≥35 |
| Lane 2 | BMI ≥30 with one of: heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension, or chronic kidney disease stage 3a or worse |
| Lane 3 | BMI ≥27 with one of: prediabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease, plus lifestyle-modification attestation |
What you actually need to do
- 1. Confirm you meet one of the three eligibility lanes above.
- 2. Ask your Kaiser provider to submit prior authorization to the CMS central processor (Humana) — not to Kaiser’s Part D plan.
- 3. Fill the prescription at a participating pharmacy. The $50/month copay applies regardless of your specific Kaiser Part D plan’s formulary.
Important Bridge caveats from the CMS FAQ: The $50 copay does not count toward your 2026 Part D annual out-of-pocket maximum, and Low-Income Subsidy (LIS) cost-sharing subsidies do not apply during the Bridge [&sup7;]. Bridging before July 1, 2026: cash-pay via LillyDirect at $149/month is the only realistic path. Three months of starter-dose cash-pay is roughly $450; after that the Bridge’s $50 copay takes over if you qualify.
For a full Medicare GLP-1 Bridge walkthrough, see: Medicare GLP-1 Bridge: everything you need to know.
Kaiser Medi-Cal members: the hardest situation, told straight
If you have Kaiser through Medi-Cal in California, Foundayo is not covered for weight loss. Medi-Cal Rx removed all GLP-1 medications from the Contract Drugs List for weight-loss indication effective January 1, 2026 [&sup8;], and Kaiser cannot override the state exclusion for its Medi-Cal members.
We’re not pretending a $149/month cash-pay offer is a real solution for most Medi-Cal households. The honest options:
- Members under 21: Medi-Cal’s EPSDT benefit can cover medically necessary medications that the standard adult formulary excludes. Discuss with your provider.
- Non-weight-loss indications: if you have Type 2 diabetes or another FDA-approved indication for a GLP-1, that’s a different coverage question and may be available under Medi-Cal.
- BALANCE Model for Medicaid: CMS opened the door for state Medicaid programs to opt into the BALANCE Model starting May 2026 [¹⁷]. California has not publicly announced participation as of April 22, 2026.
Foundayo vs. Wegovy pill vs. Zepbound — the coverage picture at Kaiser
| Drug | FDA approval (wt. loss) | Public Kaiser coverage evidence | Cash-pay starting price | Format |
|---|---|---|---|---|
| Foundayo (orforglipron) | April 1, 2026 [²] | None found in our audit | $149/mo [&sup6;] | Daily oral pill; any time of day; no food/water restrictions [¹⁸] |
| Wegovy pill (oral semaglutide) | December 2025 | Class-level Kaiser Northwest semaglutide framework [&sup5;] | $149/mo (NovoCare) | Daily oral pill; morning; limited water |
| Wegovy injection (semaglutide 2.4 mg) | 2021 | Kaiser Northwest published semaglutide criteria [&sup5;] | ~$1,350/mo without coverage | Weekly injection |
| Zepbound KwikPen (tirzepatide) | Nov 2023 (wt. loss); Dec 2024 (OSA) | Uncommon for weight loss; OSA indication improves odds | $349–$499/mo | Weekly injection |
| Ozempic (semaglutide) | Diabetes only | Kaiser covers for Type 2 diabetes with criteria | Covered path | Weekly injection |
| Mounjaro (tirzepatide) | Diabetes only | Kaiser covers for Type 2 diabetes with criteria | Covered path | Weekly injection |
Strategic read for a Kaiser member:
- If you have Type 2 diabetes, the diabetes indication path for Ozempic or Mounjaro is far stronger than any weight-loss pathway at Kaiser.
- If you have obstructive sleep apnea with obesity, Zepbound for OSA is an FDA-approved indication with its own pathway that some plans honor.
- If your interest in Foundayo is specifically the oral format with no food/water restrictions [¹⁸], that’s Foundayo’s real clinical differentiator — cite it in your exception request.
- If your interest is lowest cash-pay cost, Foundayo and the Wegovy pill both start at $149/month — cheaper than any injectable.
Foundayo medical basics — label-only summary
Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist approved by the FDA on April 1, 2026 [²] for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related medical condition, used alongside a reduced-calorie diet and increased physical activity [¹⁸]. It is the first GLP-1 pill approved with no food or water restrictions.
| Item (from FDA-approved U.S. Prescribing Information [¹⁸]) | Detail |
|---|---|
| FDA approval date | April 1, 2026 |
| Boxed warning | Thyroid C-cell tumors; do not use in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 |
| Administration | Once daily, with or without food, at any time of day |
| Concomitant GLP-1 use | Not recommended with another GLP-1 receptor agonist |
| Oral contraceptives | Switch to non-oral method OR add barrier method for 30 days after initiation AND 30 days after each dose escalation |
| Dose ladder | 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg (minimum 30 days at each step) |
| Clinical efficacy (ATTAIN-1 trial [²⁴]) | Average 12.4% body weight loss (~27.3 lbs) at highest dose over 72 weeks vs. 0.9% with placebo |
This page is about Kaiser coverage, not a prescribing guide. Read the full FDA-approved prescribing information at pi.lilly.com/us/foundayo-uspi.pdf.
What to actually do today — three paths, one decision
Path A: “I want to fight for Kaiser coverage”
- 1. Run the call script above with Member Services, then work with your Kaiser provider on a formulary exception.
- 2. If denied, file a grievance through Member Services.
- 3. California: pursue DMHC IMR for medical-necessity denials. File at healthhelp.ca.gov (free; 73% success rate in 2024).
- 4. Washington: pursue IRO external review per your EOC.
- Timeline: 2–8 weeks depending on escalation.
Path B: “I want Foundayo this month, not a fight”
- 1. Ask your Kaiser provider if they will write a prescription for external cash-pay fill.
- 2. Choose your cash-pay path: Ro (clinical support + insurance checker) or LillyDirect (lowest all-in cost, no membership).
- 3. Enroll in the Foundayo Savings Card at foundayo.lilly.com/coverage-savings if you have commercial insurance — even with no Kaiser coverage, the card caps your cost at Lilly’s published prices.
- Timeline: ~7 days.
Path C: “I have Kaiser Medicare Advantage — I’ll use the Bridge”
- 1. Confirm you meet one of the three CMS Bridge eligibility lanes: BMI ≥35; or BMI ≥30 + HFpEF/uncontrolled HTN/CKD 3a+; or BMI ≥27 + prediabetes/prior MI/prior stroke/symptomatic PAD + lifestyle attestation [&sup7;].
- 2. Have your Kaiser provider submit prior authorization to the CMS central processor starting July 1, 2026.
- 3. $50/month copay; Bridge runs through December 31, 2027.
Frequently asked questions about Kaiser and Foundayo
Does Kaiser cover Foundayo in 2026?
For most Kaiser commercial members, no public Foundayo listing was found in any of the eight 2026 Kaiser formularies we audited as of April 22, 2026. Kaiser FEHB and PSHB members have a published access framework for GLP-1s and oral anti-obesity medications at 50% coinsurance with prior authorization. Kaiser Medicare Advantage members can access Foundayo starting July 1, 2026 through the CMS Medicare GLP-1 Bridge at $50/month, independent of Kaiser’s Part D formulary.
Is Foundayo on Kaiser’s formulary right now?
As of April 22, 2026, Foundayo (orforglipron) was not found in any of the eight Kaiser Permanente 2026 formulary documents we audited — including California Commercial Marketplace, California Commercial HMO (Southern CA), Northwest Commercial, Washington Marketplace, Medicare Comprehensive, Medicare PDP (Washington), KPIC POS, and Kaiser’s member bulletin on weight-loss medication coverage.
Can my Kaiser doctor prescribe Foundayo if Kaiser doesn’t cover it?
Whether a Kaiser-affiliated provider will write a prescription for a non-formulary drug for external cash-pay fill is a clinical decision made by your individual Kaiser provider. Kaiser does not publish a formal policy on this specific question. Many members who have paid cash for Foundayo describe working with their Kaiser provider to initiate the prescription, but you should ask your provider directly. LillyDirect and Ro both accept prescriptions from any licensed U.S. provider.
How do I get a Kaiser formulary exception for Foundayo?
Your Kaiser provider submits the exception with medical-necessity documentation including BMI, comorbidities, prior weight-loss interventions, and any specific medical reasons you need an oral GLP-1. Kaiser must issue a standard decision within 72 hours of receiving your prescriber’s supporting statement, or within 24 hours for expedited requests when your health is at risk. Approval is most likely when your plan includes a weight-loss-medication benefit and your documentation matches the published criteria standard.
Does Kaiser Medicare Advantage cover Foundayo?
Kaiser’s standard Medicare Part D formularies audited do not list Foundayo, and federal law excludes pure weight-loss medications from Part D. However, the CMS Medicare GLP-1 Bridge covers Foundayo at $50/month starting July 1, 2026 through December 31, 2027 for eligible beneficiaries. Part D plans do not have to opt in for you to access the Bridge — your provider submits prior authorization to the CMS central processor, not to Kaiser’s Part D plan.
Does Kaiser Medi-Cal cover Foundayo?
No. Medi-Cal Rx excluded all GLP-1 medications for weight-loss indication effective January 1, 2026, and Kaiser Medi-Cal cannot override that state-level exclusion. Members under 21 may access GLP-1s through Medi-Cal’s EPSDT benefit under specific clinical circumstances. Adults on Medi-Cal with Type 2 diabetes may have a different coverage path through the diabetes indication.
Can I appeal a Kaiser Foundayo denial?
Yes. Kaiser has a formulary exception process, an internal grievance pathway, and — for California members — the right to file an Independent Medical Review through the DMHC when the denial is based on medical necessity. Per DMHC’s 2024 annual report, approximately 73% of submitted IMR requests resulted in the requested service or treatment being provided. Urgent IMRs are typically decided within 7 days, non-urgent within 45 days. Washington members have parallel external review through an IRO.
How much does Foundayo cost without insurance?
Foundayo’s official Lilly cash price starts at $149/month for the 0.8 mg starter dose, $199/month for 2.5 mg, and $299/month for 5.5–17.2 mg with a 45-day refill ($349/month for 14.5 mg and 17.2 mg without timely refills). Eligible patients with commercial insurance that covers Foundayo can pay as low as $25/month using the Foundayo Savings Card.
Can I use a telehealth service like Ro with Kaiser insurance?
Ro cannot function as a Kaiser in-network prescriber because Kaiser is a closed HMO — Kaiser benefits apply only when a Kaiser-affiliated provider writes the prescription. You can still use Ro as a cash-pay patient independent of your Kaiser coverage. Ro’s free GLP-1 Insurance Coverage Checker will tell you where Kaiser stands before you commit.
Is Foundayo FDA-approved?
Yes. The FDA approved Foundayo (orforglipron) on April 1, 2026. Any source describing Foundayo as “investigational” is out of date. It is a once-daily oral GLP-1 receptor agonist approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related medical condition.
How we built and verified this page
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We built this page by opening every public 2026 Kaiser formulary we could find, cross-referencing FDA and Eli Lilly source materials, and auditing current pricing from Ro, Sesame, and LillyDirect.
Documents checked on April 22, 2026:
- Kaiser 2026 California Commercial Marketplace Formulary (eff. 04/07/2026) [&sup9;]
- Kaiser 2026 California Commercial HMO Formulary, Southern CA (upd. 03/01/2026) [¹⁰]
- Kaiser 2026 Northwest Commercial Formulary (upd. 03/19/2026) [¹¹]
- Kaiser 2026 Washington Marketplace Formulary [¹²]
- Kaiser 2026 Medicare Comprehensive Formulary (eff. 04/01/2026) [¹³]
- Kaiser 2026 Medicare PDP Comprehensive Formulary, Washington [¹⁴]
- Kaiser Permanente Insurance Company (KPIC) POS Formulary [¹⁵]
- Kaiser Northwest semaglutide (Wegovy) coverage criteria [&sup5;]
- Kaiser FEHB / PSHB Weight Management Programs and GLP-1 Requirements [&sup4;]
- Kaiser “Your weight loss medication coverage” member bulletin [¹⁶]
- Kaiser 2025 California Individual and Family Evidence of Coverage [³]
- FDA Foundayo approval announcement, April 1, 2026 [²]
- Foundayo U.S. Prescribing Information, Eli Lilly, April 2026 [¹⁸]
- Foundayo coverage and savings page, foundayo.lilly.com [&sup6;]
- CMS Medicare GLP-1 Bridge page, last modified April 21, 2026 [&sup7;]
- CMS BALANCE Model page, last modified April 22, 2026 [¹⁷]
- Medi-Cal Rx GLP-1 exclusion policy, effective January 1, 2026 [&sup8;]
- DMHC 2024 Annual Report and Help Center FAQ [²¹] [²²]
- Ro Foundayo and GLP-1 Insurance Coverage Checker pages [¹⁹] [²³]
- ATTAIN-1 trial (Wharton et al., NEJM, November 6, 2025) [²⁴]
Re-verification cadence: monthly for Kaiser formulary status and all cash-pay pricing; immediate trigger for FDA safety updates, Kaiser P&T Committee announcements, and CMS Bridge FAQ updates.
Related pages on The RX Index
Ready to stop guessing and get a real answer?
Ro’s free GLP-1 Insurance Coverage Checker contacts your insurer and emails you a personalized report on coverage status and prior authorization. No charge, no obligation to become a patient.
Use Ro’s free GLP-1 Insurance Coverage Checker →For commercial and FEP Blue members. Medicare Advantage / Medi-Cal members: see plan-specific sections above.
Written by The RX Index Editorial Team. This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult your healthcare provider about whether Foundayo is appropriate for you. Last verified: April 22, 2026. Ro discloses on its public pages that member testimonials were compensated; any Ro testimonials on this page are presented with that disclosure.